Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313653 | 0.76 | — | — | |
| SCHEMBL4017065 | 0.73 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL87566 | 0.60 | — | — | |
| SCHEMBL29026457 | 0.58 | — | — | |
| SCHEMBL29000323 | 0.58 | CYP2C19 (0.35) | — | |
| SCHEMBL1651627 | 0.56 | — | — | |
| SCHEMBL572320 | 0.56 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19439409 | 0.55 | SLC6A4 (0.30) | — | |
| SCHEMBL18052040 | 0.55 | EPHX1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8958407 | 0.55 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114558032-A | Method for preparing platelets from pluripotent stem cells and composition thereof | 安斯泰来再生医药协会 | 2022-05-31 | — | — | CN | disclosed |
| CN-105101979-B | Method for preparing platelets from pluripotent stem cells and composition thereof | 安斯泰来再生医药协会 | 2021-10-08 | — | — | CN | disclosed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10265374-B2 | Occidiofungin formations and uses thereof | MISSISSIPPI STATE UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170281721-A1 | OCCIDIOFUNGIN FORMATIONS AND USES THEREOF | MISSISSIPPI STATE UNIVERSITY (US) | 2017-10-05 | — | — | US | disclosed |
| EP-3191114-A1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | Smith, James (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040940-A1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | AUSTIN, FRANK (US) | 2016-03-17 | — | — | WO | disclosed |
| US-8476246-B2 | Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system | ANTISENSE PHARMA GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120027873-A1 | COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN INHIBITOR OF THE TGF-BETA SYSTEM | ANTISENSE PHARMA GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2340308-A1 | COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN INHIBITOR OF THE TGF-BETA SYSTEM | Antisense Pharma GmbH (DE) | 2011-07-06 | — | — | EP | disclosed |
| US-20070196269-A1 | Pharmaceutical composition | ANTISENSE PHARMA GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1694840-A2 | COMBINATION THERAPY ASSOCIATING A TGF-BETA ANTAGONIST WITH A CHEMOTHERAPEUTIC AGENT | Antisense Pharma GmbH (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-6949350-B1 | Chemosensitivity determination using phosphatidylserine | EVOTEC ANALYTICAL SYSTEMS GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005059133-A2 | COMBINATION THERAPY ASSOCIATING A TGF-BRETA ANTAGONIST WITH A CHEMIOTHERAPEUTIC AGENT | ANTISENSE PHARMA GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-0525188-B1 | LIPOSOME COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5252336-A | Good dispersibility; high stability; high encapsulation properties | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| EP-0525188-A1 | LIPOSOME COMPOSITION. | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016040-A1 | LIPOSOME COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | ALDH1A1 995/4885SMN1; SMN2 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.